J&J's Invega is first drug approved for schizoaffective disorder in US
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's Invega (paliperidone) extended-release tablets have become the first antipsychotic approved by the US FDA for the treatment of schizoaffective disorder, as monotherapy or an adjunctive to mood stabilisers and/or antidepressants.